Bastiaans J, et al. - Researchers attempted to inspect the capacity of the clinically available direct thrombin inhibitor dabigatran to inhibit thrombin activity in vitreous fluids. A correlation was brought to light between proliferative vitreoretinopathy (PVR) with increased intravitreal thrombin activity which activated the profibrotic and proinflammatory pathways in RPE cells. This activation pathway exhibited the potential of being inhibited by dabigatran.